About Cerevast Therapeutics
Cerevast Therapeutics is developing a non-invasive treatment for acute ischemic stroke known as sonothrombolysis, or SonoLysis for short. This treatment harnesses the acoustic energy from externally applied ultrasound to treat stroke-causing clots in the blood vessels of the brain. The company has developed an operator-independent ultrasonic headframe called the ClotBust-ER. This device can be rapidly and easily deployed by virtually any emergency room staff to safely administer the ultrasound energy for SonoLysis therapy.
Cerevast Therapeutics Patents
Cerevast Therapeutics has filed 5 patents.
Ion channels, Neurophysiology, Membrane biology, Neurotechnology, Acoustics
Ion channels, Neurophysiology, Membrane biology, Neurotechnology, Acoustics
Latest Cerevast Therapeutics News
Jan 27, 2023
(Longevity Photo) Bradford Zakes recently helped combine the Seattle-area biotech company he led, Cerevast Medical , with two startups to create a new company. Now he’s poised to take Longevity Biomedical public as its president and CEO, via a merger with a shell company. The merger is expected to raise at least $30 million for Bothell, Wash.-based Longevity. The deal, which merges Longevity with a SPAC (special purpose acquisition company), is expected to close in the second quarter of this year. Longevity combines Cerevast with NovoKera, a Nevada startup, and Aegeria Soft Tissue, a Johns Hopkins University spinout. The common theme is helping aging people lead healthier, longer lives, Zakes said in an interview with GeekWire. “We think we’ve pulled together a really attractive portfolio of assets,” Zakes said. Longevity’s pipeline now includes Cerevast’s experimental treatments for stroke and retinal vein occlusion, a common cause of blindness; Aegeria’s experimental product for soft-tissue reconstruction; and Novokera’s preclinical product for corneal blindness. Longevity is developing treatments and products to “increase health span” for aging individuals, according to a statement Thursday announcing the SPAC deal. Longevity will acquire all outstanding equity securities of the two other startups as part of the SPAC deal in exchange for shares of common stock of Longevity. The combined company is expected to be valued at $236.2 million. The SPAC deal may also raise an additional $30 million through a pre-transaction PIPE (private investment in public equity). “This has not been an easy one by any stretch,” Zakes said of the series of transactions. “It’s been a long time to get to this stage.” Longevity’s management team pulls its chief technology officer, Francesco Curra , from Cerevast and its chief operating officer, Anthony Lee, from NovoKera. Longevity hired Brenda Sparks , previously the corporate controller at Cancer Prevention Pharmaceuticals, as chief financial officer. Longevity is still planning the transition, but Zakes said some employees of the other startups will probably relocate to the Seattle area. Cerevast’s six employees are coming on board, and Longevity plans to hire more with proceeds from the SPAC merger, which is expected to fuel the company into 2025. The investment bank US Tiger Securities is behind the shell company involved in the SPAC deal, Denali Capital Acquisition Corp., whose CEO is Lei Huang , CEO of Tiger Securities. The deal comes during a massive downturn in tech and a cooling biotech market. According to Endpoints News’ IPO tracker , last year only 25 biotech companies went public, 12 via a SPAC merger, compared to the 147 biotech companies that went public in 2021, 48 via SPAC. No biotech company has yet completed an IPO in 2023. More than 55 SPAC transactions were also called off in 2022, including a deal involving Seattle startup Intrinsic Medicine. Zakes is looking to the long term, with plans to acquire additional assets related to longevity. “Our intention is to not stop with these core assets, but rather to continue to be very opportunistic and look for additional technologies, products, as well as partnerships with companies to broaden our portfolio,” said Zakes. Zakes is a former executive at ICOS Corporation, a Seattle biotech company bought by Eli Lilly in 2007 for $2.3 billion. He was also previously president and CEO at ImaRx Therapeutics, whose assets were acquired by Cerevast at its launch in 2009, when he became CEO. Longevity’s ultimate aim, said Zakes, is to become a “one-stop shop for consumers of longevity-related products and services.” The company also has its eye on the market in low- to middle-income countries. The new startup enters a field that includes giant longevity biotech company Altos Labs, which is fueled by a $3 billion investment, and Calico Life Sciences, a subsidiary of Google parent company Alphabet. Longevity provides a unique set of technologies, said Zakes, including ultrasound technology developed by Cerevast. Longevity’s pipeline includes: A potential treatment for stroke that combines transcranial ultrasound with conventional anti-clotting therapy to break up clots and restore blood flow. A retinal vein occlusion treatment that combines ultrasound with gas-filled microspheres currently on the market; the microspheres expand and contract to help break up clots. A biosynthetic tissue scaffold that has the potential for use in soft tissue reconstruction to help fill out aging tissue or after surgery for breast cancer and other conditions. A biosynthetic cornea that has the potential to supplant current treatments, which involve transplantation with human corneas. In the near term, Longevity plans to use the cash to complete a phase 3 study of its candidate for ischemic stroke, phase 2 studies for its candidates for retinal vein occlusion and soft tissue reconstruction, and complete preclinical studies for its biosynthetic cornea. Charlotte Schubert is a GeekWire reporter and science journalist with a focus on biotech, healthcare, and life sciences. She is a Seattle native, former editor at Nature Medicine, and recovering lab rat. Follow her on LinkedIn or reach her at firstname.lastname@example.org . Share
Cerevast Therapeutics Frequently Asked Questions (FAQ)
When was Cerevast Therapeutics founded?
Cerevast Therapeutics was founded in 2009.
Where is Cerevast Therapeutics's headquarters?
Cerevast Therapeutics's headquarters is located at 11601 Willows Road, Redmond.
What is Cerevast Therapeutics's latest funding round?
Cerevast Therapeutics's latest funding round is Series D.
How much did Cerevast Therapeutics raise?
Cerevast Therapeutics raised a total of $23.32M.
Who are the investors of Cerevast Therapeutics?
Investors of Cerevast Therapeutics include Genstar Capital, Kearny Venture Partners, Haiyin Capital and Qualifying Therapeutic Discovery Project.
Who are Cerevast Therapeutics's competitors?
Competitors of Cerevast Therapeutics include Kiyatec, TheraVida, Armgo Pharma, Promedior, Sarentis Therapeutics and 11 more.
Compare Cerevast Therapeutics to Competitors
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).
Excelimmune is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. This next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens.
Allozyne is a protein optimization company committed to the development of improved biological therapeutics to treat multiple areas of unmet medical need. Allozyne's two technology platforms enable the incorporation of amino acids analogues, at any specified position, into existing biologics leading to improved efficacy, tolerability and pharmacology.
Sarentis is a start-up biopharmaceutical company focused on the development of therapeutics for the treatment of pain.
Curemark is a research-driven biotechnology company that develops and markets products to fulfill needs in neurological medicine. The company is committed to improving the quality of life for children and adults with neurological disorders by providing safe, effective and clinically proven solutions. The company's flagship product is focused on treating children with autism. Curemark was is based in Rye, New York.